Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA Continues Call For Downgrade In Thai Trade Status

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Once again the U.S. pharmaceutical industry has requested the U.S. government to downgrade Thailand's trade status due to intellectual property rights violations. The downgrade would subject Thai exports to higher tariffs and a loss of tax privileges in the U.S

You may also be interested in...

Sanofi Asks Thailand To Review Compulsory Licensing Policy

Sanofi-Aventis sent a request to the previous Thai Minister of Commerce Mingkwan Sangsuwan to review the process of compulsory licensing on patented drugs, Graham Almond, Sanofi-Aventis Thailand general manager told PharmAsia News.

Thai Officials Say Compulsory Licenses Will Not Deter Biotech Business – BIO 2008 Exclusive

SAN DIEGO - Industry furor over Thailand's compulsory license position will not deter multinational companies from investing in the country, according to Thai officials who sat down with PharmAsia News during the BIO 2008 convention in San Diego

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts